What Researchers Did
Researchers conducted a systematic review to identify and describe ocular adverse events associated with pharmacological treatments for multiple sclerosis.
What They Found
Out of 2852 initial articles, 67 met the inclusion criteria, comprising 11 experimental and 56 observational studies. They found that alemtuzumab, amantadine, fingolimod, steroids, interferon β, natalizumab, rituximab, siponimod, and teriflunomide were among the therapies linked to ocular treatment-emergent adverse events.
What This Means for Canadian Patients
Canadian patients with multiple sclerosis should be aware of potential ocular side effects when undergoing pharmacological treatment. Healthcare providers should monitor for these adverse events and discuss them with patients to manage expectations and ensure timely intervention.
Canadian Relevance
This study has no direct Canadian connection as it did not involve Canadian researchers, patients, or institutions.
Study Limitations
The study's narrative synthesis approach may limit the ability to quantitatively compare the frequency or severity of ocular adverse events across different treatments.